Jundishapur Journal of Chronic Disease Care
Volume 13 · Issue 3 · e142669

OPEN PEER REVIEW

Survival Rate of Hemodialysis Patients and Its Predictors: A Multicentric Retrospective Cohort Study

Sahar Ahmadi Valiabadi, Seyedehzahra Hosseinigolafshani, Mehdi Ranjbaran

SUBMITTED	REVISED	ACCEPTED	DOI
4 Nov 2023	13 Jan 2024	8 Mar 2024	10.5812/jjcdc-142669

About this report

This open peer review (OPR) report shows the public comments made on this article during peer review, by the reviewers, the associate editor and the editor-in-chief, for every revision round, together with the authors' replies. Comments appear only with the consent of the people who wrote them. Reviewers who chose to sign their report are named; the others are shown as "Referee". Comments are edited for language only, and confidential remarks to the editors are not included.

More about open peer review: brieflands.com/knowledgebase/opr

Contents

1 **Original submission** Associate Editor, Editor-in-Chief 2
2 **Revision 1** Referee 1, Associate Editor, Editor-in-Chief 4
Authors' reply to reviewers 5
Reviewer and editor comments 8

1 Original submission

3 comments · 7 Nov 2023 – 29 Dec 2023

Associate Editor

REJECT 7 Nov 2023

Dear author
The editorial team of the Jundishapur Journal of Chronic Disease Care has concluded that your manuscript entitled “Survival Rate of Hemodialysis Patients and Its Predictors; A Multi centric retrospective cohort stud” is not suitable for publication in the Jundishapur Journal of Chronic Disease Care based on several points of consideration including referee comments, scientific merit, recent work on a similar topic that may have appeared in Jundishapur Journal of Chronic Disease Care, and competition for a limited number of printed pages.
We appreciate the fact that you have considered Jundishapur Journal of Chronic Disease Care for the publication of your work.

Associate Editor

MAJOR REVISION 29 Dec 2023

Dear Author,
Thank you for submitting your manuscript to JJCDC. This manuscript has an essential problem that must be resolved before the final decision.

1# Title and abstract
- The title is good.
- In the abstract, you should explain more about your method. You stated that this is a cohort study, but the methods section does not clearly explain the cohort details. Is this a part of the Persian Cohort? What is the registration?

#2 Background / Rationale
Explain the scientific background and rationale for the investigation being reported.
#3 Objectives
Please state the objectives, including any prespecified hypotheses, at the end of the introduction. Please see the published articles.

#3 Methods
-Study design
Present key elements of the study design early in the paper.
-Setting: Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.
-Eligibility criteria: Give the eligibility criteria and the sources and methods of selection of participants. Describe methods of follow-up.
Eligibility criteria: Did you use any matching? Give the matching criteria and the number of exposed and unexposed participants.
Variables.
-Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria.
-Data sources/measurement: For each variable of interest, give data sources and details of assessment methods (measurement).
-Describe the comparability of assessment methods if there is more than one group. Give information

separately for exposed and unexposed groups if applicable.
-Bias: Describe any efforts to address potential sources of bias.
-Study size: Explain how the study size was determined or provide the sample size formula.
Statistical Methods
-Describe all statistical methods, including those used to control for confounding.
Statistical methods

#4 Results
-Descriptive data: Summarize follow-up time (e.g., average and total amount).
-Outcome data: Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.
-Give unadjusted estimates and confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included.
-If you can, consider translating estimates of relative risk into absolute risk for a meaningful period.

#5 Discussion
-Present the key results concerning the study objectives at the beginning of the study.
-Limitations: Discuss the limitations of the study, considering sources of potential bias or imprecision. Discuss both the direction and magnitude of any potential bias.
-Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.
-Discuss the generalizability (external validity) of the study results and provide some implications.
Thank you

Editor-in-Chief

MAJOR REVISION 29 Dec 2023

Dear Author,
Thank you for submitting your manuscript to JJCDC. Based on our reviewers' comments, your article needs some revisions throughout. Please use previously published related articles in your references. I recommend you revise the manuscript and resubmit it as soon as possible.
With regards.

2

Revision 1

AUTHORS' RESPONSE TO REVIEWERS

Authors' reply to reviewers

The next pages contain the authors' point-by-point reply to the comments of this revision round, as submitted with the revised manuscript. It is published as the authors wrote it.

Dear Editor-in-Chief of the Jundishapur Journal Of Chronic Disease Care

Thank you for your thorough review and consideration of our Manuscript ID.142669 entitled " Survival Rate of Hemodialysis Patients and Its Predictors; A Multi centric retrospective cohort study" which was submitted to the Jundishapur Journal Of Chronic Disease Care.
We have modified the manuscript based on the reviewer's comments, and detailed corrections are listed below point by point.

1- *in the abstract, you should explain more about your method. you told me the method is cohort but in the method, there is no clear explanation about the cohort details. Is this a part of the Persian Cohort? what is registration?*
Thank you for your comment, This section has been revised and highlighted.

2- *Background / Rationale ..Explain the scientific background and rationale for the investigation being reported*
Thank you for your attention. In this regard, two paragraphs have been added at the end of the introduction

3- *Please estate objectives, including any prespecified hypotheses at the end of the introduction. Please see the published articles.*
The comment was applied

4- *Present key elements of study design early in the paper*
-Setting: Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
The comment was applied

5- *Eligibility criteria: Give the eligibility criteria and the sources and methods of selection of participants.*

Describe methods of follow-up.
The comment was applied.

6- *Eligibility criteria: Do you have any matching? give matching criteria and the number of exposed and unexposed*

Variables.
Our study did not employ a matching approach in the selection of exposed and unexposed participants. Therefore, we do not have matching criteria to report. I hope this provides the clarity needed, and I'm available for any further questions or details.

7. Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria
The comment was applied.

8. Data sources/measurement: For each variable of interest, give data sources and details of assessment methods (measurement).

The comment was applied.

9. Describe comparability of assessment methods if there is more than one group. Give information separately for exposed and unexposed groups if applicable

In this study, we did not have more than one group. The details of the studied group are mentioned in the methodology of the article.

10. Bias: Describe any efforts to address potential sources of bias

This comment has been modified in the article

11. Study size: Explain how the study size has arrived or the sample size formula.

We have added formula and estimation of sample size.

12. Statistical Methods-Describe all statistical methods, including those used to control for confounding

It is presented in the statistical analysis section

13. Descriptive data: Summarise follow-up time (eg, average and total amount)

The mean follow-up time was 22.82±16.65 months that are presented in results.

14. Outcome data: Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable

Clinical characteristics of patients are presented in Table 1 separately for exposed and unexposed groups.

15. Give unadjusted estimates and, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included

Unadjusted estimates and, confounder-adjusted estimates and their precision are presented in table 2 and 3 respectively. Variables with p-values≤0.2 in univariable Cox regression were included in the multivariable Cox regression model.

16. If you can, consider translating estimates of relative risk into absolute risk for a meaningful period

In the Multivariable Cox regression analysis section Hazard ratio are presented as absolute risk.

17. Discussion

-Bring key results concerning study objectives in the first of the study
-Limitations: Discuss the limitations of the study, considering sources of potential bias or imprecision. Discuss both the direction and magnitude of any potential bias.
-Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.
-Discuss the generalisability (external validity) of the study results and bring some implications.
Thank you

Thanks for your valuable attention, All comments in the discussion section have been revised and highlighted.

3

2 Revision 1

3 comments · 4 Mar 2024 – 8 Mar 2024

Referee 1 Reviewer

ACCEPT 4 Mar 2024

Dear Author,
All comments have been made, and this manuscript in the current format is acceptable for publication.
Thank you

Associate Editor

ACCEPT 8 Mar 2024

Dear Author,
All comments have been addressed, and this manuscript in its current version is acceptable.
Thank you

Editor-in-Chief

ACCEPT 8 Mar 2024

Dear Author,
Your manuscript in the current version is acceptable for publication.
Thank you